The article discusses the emergence of cancer diagnostic tests which perform network profilin. It explains two new proteomic diagnostic tests. The first is single-cell network profiling (SCNP) which was developed by biotechnology company Nodality. The second is nanofluidic proteomic immunoassay (NIA), developed by Dean Felsher at Stanford University with the help of biotechnology company Cell Biosciences.